Compare Recursion Pharmaceuticals Inc (RXRX) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Shopify Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $4.06 (market cap $2.14B), while Shopify Inc. trades at $166.06 (market cap $211.73B). The key difference: Shopify Inc. is far larger — about 98.9× Recursion Pharmaceuticals Inc's market cap, and Shopify Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Shopify Inc. for 78 Days on average.
| RXRX | SHOP | |
|---|---|---|
Market Cap | $2.14B | $211.73B |
Volume | 30,789,535 | 7,146,651 |
Sector | Health | Technology |
52-Week High | $6.79 | $179.01 |
52-Week Low | $2.84 | $95.40 |
Typical Hold Time | 22 Days | 78 Days |
Enterprise Value | $1.66B | $206.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
SHOP trades at $165.94, up 0.88% with strong bullish momentum near its consensus price target of $168.63. The stock shows robust revenue growth from $5.6B in 2022 to $11.6B in 2025, with net income turning positive to $1.23B. Technical indicators show bullish moving averages but overbought RSI levels, while fundamental valuation remains elevated with P/E of 111.19. Recent developments include Shopify's AI-powered Canvas platform launch and strategic positioning in the AI commerce space.
Outlook remains positive with 67% analyst buy ratings and projected revenue growth to $13.3B in 2026. Key opportunities include merchant solutions growth and AI integration, while risks include high valuation multiples and competitive pressures from Amazon. The stock presents growth potential but requires monitoring of execution and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
